Overview

A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants With Alpha (α)-Thalassemia

Status:
Recruiting
Trial end date:
2026-06-18
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the efficacy and safety of luspatercept plus best supportive care (BSC) vs placebo plus BSC on anemia in participants with α-thalassemia hemoglobin H (HbH) disease.
Phase:
Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Luspatercept